Neurochemical evidence that stimulation of CB1 cannabinoid receptors on GABAergic nerve terminals activates the dopaminergic reward system by increasing dopamine release in the rat nucleus accumbens
We examined the effect of cannabinoid receptor activation on basal and electrical field simulation-evoked (25 V, 2 Hz, 240 shocks) [ 3H]dopamine efflux in the isolated rat nucleus accumbens in a preparation, in which any effect on the dendrites or somata of ventral tegmental projection neurons was e...
Gespeichert in:
Veröffentlicht in: | Neurochemistry international 2009-06, Vol.54 (7), p.452-457 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 457 |
---|---|
container_issue | 7 |
container_start_page | 452 |
container_title | Neurochemistry international |
container_volume | 54 |
creator | Sperlágh, Beáta Windisch, Katalin Andó, Rómeó D. Sylvester Vizi, E. |
description | We examined the effect of cannabinoid receptor activation on basal and electrical field simulation-evoked (25
V, 2
Hz, 240 shocks) [
3H]dopamine efflux in the isolated rat nucleus accumbens in a preparation, in which any effect on the dendrites or somata of ventral tegmental projection neurons was excluded. The cannabinoid agonist (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone mesylate (WIN55,212-2, 100
nM) significantly enhanced stimulation-evoked [
3H]dopamine release in the presence of the selective dopamine transporter inhibitor 1-[2-[bis-(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine dihydrochloride (GBR12909, 100
nM). GBR12909 (100
nM–1
μM), when added alone, increased the evoked [
3H]dopamine efflux in a concentration-dependent manner. The stimulatory effect of WIN55,212-2 on the evoked tritium efflux was inhibited by the selective CB1 cannabinoid receptor antagonist N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (AM251, 100
nM) and by the GABA
A receptor antagonist bicuculline (10
μM). Repeated application of N-methyl-
d aspartate (1
mM) under Mg
2+-free conditions, which directly acts on dopaminergic terminals, reversibly increased the tritium efflux, but WIN55,212-2 did not affect N-methyl-
d aspartate-evoked [
3H]dopamine efflux, indicating that WIN55,212-2 has no direct action on dopaminergic nerve terminals. AM251 (100
nM) alone also did not have an effect on electrical stimulation-evoked [
3H]dopamine efflux. Likewise, the selective CB2 receptor antagonist 6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl)methanone (AM630, 0.3
μM) and the anandamide transport inhibitor (5Z,8Z,11Z,14Z)-N-(4-hydroxy-2-methylphenyl)-5,8,11,14-eicosatetraenamide (VDM11, 10
μM) had no significant effect on electrically evoked [
3H]dopamine release.
This is the first neurochemical evidence that the activation of CB1 cannabinoid receptors leads to the augmentation of [
3H]dopamine efflux via a local GABA
A receptor-mediated disinhibitory mechanism in the rat nucleus accumbens. |
doi_str_mv | 10.1016/j.neuint.2009.01.017 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67228845</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0197018609000357</els_id><sourcerecordid>20068399</sourcerecordid><originalsourceid>FETCH-LOGICAL-c421t-bb943afc2c45990f66dfc4c51c00d7b0684d01744b8c17b5b3f7a3cea4d77a873</originalsourceid><addsrcrecordid>eNqFksFu1DAQhiMEokvhDRDyBW5Z7MSJ7QvSdgUtUgUXOFvOeNJ6lTiL7Wy1L8hz4XRX5QbSSJY83_z-Nb-L4i2ja0ZZ-3G39jg7n9YVpWpNWS7xrFgxKapSiYY_L1aUKVFSJtuL4lWMO0qpULR5WVwwxSsppFwVv7_hHCa4x9GBGQgenEUPSNK9SSQmN86DSW7yZOrJ9ooRMN6bzvnJWRIQcJ-mEEnuX2-uNhjuHBCP4ZAFMIzOmyESA8kdTMKYRZHYaW9y44QGfDDBkniMCUfSHYnzENBE5--ewAwN-Qpz71EgZGN-hgHnRRrmsUMfXxcv-vwWvjmfl8XPL59_bG_K2-_XX7eb2xJ4xVLZdYrXpocKeKMU7dvW9sChYUCpFR1tJbd5jZx3Epjomq7uhakBDbdCGCnqy-LDSXcfpl8zxqRHFwGHwXic5qhbUVVS8ua_YA6tlbVSGeQnEMIUY8Be74MbTThqRvUStN7pU9DLjNKU5VqMvDvrz92I9u_QOdkMvD8DJuZk-2A8uPjEVayWnMvF6KcTh3ltB4dBR3DLF7Au55u0ndy_nfwB1iHOOA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20068399</pqid></control><display><type>article</type><title>Neurochemical evidence that stimulation of CB1 cannabinoid receptors on GABAergic nerve terminals activates the dopaminergic reward system by increasing dopamine release in the rat nucleus accumbens</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Sperlágh, Beáta ; Windisch, Katalin ; Andó, Rómeó D. ; Sylvester Vizi, E.</creator><creatorcontrib>Sperlágh, Beáta ; Windisch, Katalin ; Andó, Rómeó D. ; Sylvester Vizi, E.</creatorcontrib><description>We examined the effect of cannabinoid receptor activation on basal and electrical field simulation-evoked (25
V, 2
Hz, 240 shocks) [
3H]dopamine efflux in the isolated rat nucleus accumbens in a preparation, in which any effect on the dendrites or somata of ventral tegmental projection neurons was excluded. The cannabinoid agonist (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone mesylate (WIN55,212-2, 100
nM) significantly enhanced stimulation-evoked [
3H]dopamine release in the presence of the selective dopamine transporter inhibitor 1-[2-[bis-(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine dihydrochloride (GBR12909, 100
nM). GBR12909 (100
nM–1
μM), when added alone, increased the evoked [
3H]dopamine efflux in a concentration-dependent manner. The stimulatory effect of WIN55,212-2 on the evoked tritium efflux was inhibited by the selective CB1 cannabinoid receptor antagonist N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (AM251, 100
nM) and by the GABA
A receptor antagonist bicuculline (10
μM). Repeated application of N-methyl-
d aspartate (1
mM) under Mg
2+-free conditions, which directly acts on dopaminergic terminals, reversibly increased the tritium efflux, but WIN55,212-2 did not affect N-methyl-
d aspartate-evoked [
3H]dopamine efflux, indicating that WIN55,212-2 has no direct action on dopaminergic nerve terminals. AM251 (100
nM) alone also did not have an effect on electrical stimulation-evoked [
3H]dopamine efflux. Likewise, the selective CB2 receptor antagonist 6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl)methanone (AM630, 0.3
μM) and the anandamide transport inhibitor (5Z,8Z,11Z,14Z)-N-(4-hydroxy-2-methylphenyl)-5,8,11,14-eicosatetraenamide (VDM11, 10
μM) had no significant effect on electrically evoked [
3H]dopamine release.
This is the first neurochemical evidence that the activation of CB1 cannabinoid receptors leads to the augmentation of [
3H]dopamine efflux via a local GABA
A receptor-mediated disinhibitory mechanism in the rat nucleus accumbens.</description><identifier>ISSN: 0197-0186</identifier><identifier>EISSN: 1872-9754</identifier><identifier>DOI: 10.1016/j.neuint.2009.01.017</identifier><identifier>PMID: 19428788</identifier><identifier>CODEN: NEUIDS</identifier><language>eng</language><publisher>Kidlington: Elsevier Ltd</publisher><subject>Anandamide ; Animals ; Benzoxazines - pharmacology ; Bicuculline - pharmacology ; Biological and medical sciences ; Cannabinoid ; CB1 receptor ; Dopamine ; Dopamine - metabolism ; Dopamine - physiology ; Electric Stimulation ; Fundamental and applied biological sciences. Psychology ; GABA ; GABA Antagonists - pharmacology ; GABA-A Receptor Antagonists ; gamma-Aminobutyric Acid - physiology ; Male ; Morpholines - pharmacology ; Naphthalenes - pharmacology ; Nerve Endings - drug effects ; Nucleus accumbens ; Nucleus Accumbens - drug effects ; Nucleus Accumbens - metabolism ; Piperidines - pharmacology ; Pyrazoles - pharmacology ; Rats ; Rats, Wistar ; Receptor, Cannabinoid, CB1 - agonists ; Release ; Reward ; Vertebrates: nervous system and sense organs</subject><ispartof>Neurochemistry international, 2009-06, Vol.54 (7), p.452-457</ispartof><rights>2009 Elsevier Ltd</rights><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c421t-bb943afc2c45990f66dfc4c51c00d7b0684d01744b8c17b5b3f7a3cea4d77a873</citedby><cites>FETCH-LOGICAL-c421t-bb943afc2c45990f66dfc4c51c00d7b0684d01744b8c17b5b3f7a3cea4d77a873</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.neuint.2009.01.017$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21384485$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19428788$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sperlágh, Beáta</creatorcontrib><creatorcontrib>Windisch, Katalin</creatorcontrib><creatorcontrib>Andó, Rómeó D.</creatorcontrib><creatorcontrib>Sylvester Vizi, E.</creatorcontrib><title>Neurochemical evidence that stimulation of CB1 cannabinoid receptors on GABAergic nerve terminals activates the dopaminergic reward system by increasing dopamine release in the rat nucleus accumbens</title><title>Neurochemistry international</title><addtitle>Neurochem Int</addtitle><description>We examined the effect of cannabinoid receptor activation on basal and electrical field simulation-evoked (25
V, 2
Hz, 240 shocks) [
3H]dopamine efflux in the isolated rat nucleus accumbens in a preparation, in which any effect on the dendrites or somata of ventral tegmental projection neurons was excluded. The cannabinoid agonist (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone mesylate (WIN55,212-2, 100
nM) significantly enhanced stimulation-evoked [
3H]dopamine release in the presence of the selective dopamine transporter inhibitor 1-[2-[bis-(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine dihydrochloride (GBR12909, 100
nM). GBR12909 (100
nM–1
μM), when added alone, increased the evoked [
3H]dopamine efflux in a concentration-dependent manner. The stimulatory effect of WIN55,212-2 on the evoked tritium efflux was inhibited by the selective CB1 cannabinoid receptor antagonist N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (AM251, 100
nM) and by the GABA
A receptor antagonist bicuculline (10
μM). Repeated application of N-methyl-
d aspartate (1
mM) under Mg
2+-free conditions, which directly acts on dopaminergic terminals, reversibly increased the tritium efflux, but WIN55,212-2 did not affect N-methyl-
d aspartate-evoked [
3H]dopamine efflux, indicating that WIN55,212-2 has no direct action on dopaminergic nerve terminals. AM251 (100
nM) alone also did not have an effect on electrical stimulation-evoked [
3H]dopamine efflux. Likewise, the selective CB2 receptor antagonist 6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl)methanone (AM630, 0.3
μM) and the anandamide transport inhibitor (5Z,8Z,11Z,14Z)-N-(4-hydroxy-2-methylphenyl)-5,8,11,14-eicosatetraenamide (VDM11, 10
μM) had no significant effect on electrically evoked [
3H]dopamine release.
This is the first neurochemical evidence that the activation of CB1 cannabinoid receptors leads to the augmentation of [
3H]dopamine efflux via a local GABA
A receptor-mediated disinhibitory mechanism in the rat nucleus accumbens.</description><subject>Anandamide</subject><subject>Animals</subject><subject>Benzoxazines - pharmacology</subject><subject>Bicuculline - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Cannabinoid</subject><subject>CB1 receptor</subject><subject>Dopamine</subject><subject>Dopamine - metabolism</subject><subject>Dopamine - physiology</subject><subject>Electric Stimulation</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>GABA</subject><subject>GABA Antagonists - pharmacology</subject><subject>GABA-A Receptor Antagonists</subject><subject>gamma-Aminobutyric Acid - physiology</subject><subject>Male</subject><subject>Morpholines - pharmacology</subject><subject>Naphthalenes - pharmacology</subject><subject>Nerve Endings - drug effects</subject><subject>Nucleus accumbens</subject><subject>Nucleus Accumbens - drug effects</subject><subject>Nucleus Accumbens - metabolism</subject><subject>Piperidines - pharmacology</subject><subject>Pyrazoles - pharmacology</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Receptor, Cannabinoid, CB1 - agonists</subject><subject>Release</subject><subject>Reward</subject><subject>Vertebrates: nervous system and sense organs</subject><issn>0197-0186</issn><issn>1872-9754</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFksFu1DAQhiMEokvhDRDyBW5Z7MSJ7QvSdgUtUgUXOFvOeNJ6lTiL7Wy1L8hz4XRX5QbSSJY83_z-Nb-L4i2ja0ZZ-3G39jg7n9YVpWpNWS7xrFgxKapSiYY_L1aUKVFSJtuL4lWMO0qpULR5WVwwxSsppFwVv7_hHCa4x9GBGQgenEUPSNK9SSQmN86DSW7yZOrJ9ooRMN6bzvnJWRIQcJ-mEEnuX2-uNhjuHBCP4ZAFMIzOmyESA8kdTMKYRZHYaW9y44QGfDDBkniMCUfSHYnzENBE5--ewAwN-Qpz71EgZGN-hgHnRRrmsUMfXxcv-vwWvjmfl8XPL59_bG_K2-_XX7eb2xJ4xVLZdYrXpocKeKMU7dvW9sChYUCpFR1tJbd5jZx3Epjomq7uhakBDbdCGCnqy-LDSXcfpl8zxqRHFwGHwXic5qhbUVVS8ua_YA6tlbVSGeQnEMIUY8Be74MbTThqRvUStN7pU9DLjNKU5VqMvDvrz92I9u_QOdkMvD8DJuZk-2A8uPjEVayWnMvF6KcTh3ltB4dBR3DLF7Au55u0ndy_nfwB1iHOOA</recordid><startdate>20090601</startdate><enddate>20090601</enddate><creator>Sperlágh, Beáta</creator><creator>Windisch, Katalin</creator><creator>Andó, Rómeó D.</creator><creator>Sylvester Vizi, E.</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7U7</scope><scope>C1K</scope><scope>7X8</scope></search><sort><creationdate>20090601</creationdate><title>Neurochemical evidence that stimulation of CB1 cannabinoid receptors on GABAergic nerve terminals activates the dopaminergic reward system by increasing dopamine release in the rat nucleus accumbens</title><author>Sperlágh, Beáta ; Windisch, Katalin ; Andó, Rómeó D. ; Sylvester Vizi, E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c421t-bb943afc2c45990f66dfc4c51c00d7b0684d01744b8c17b5b3f7a3cea4d77a873</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Anandamide</topic><topic>Animals</topic><topic>Benzoxazines - pharmacology</topic><topic>Bicuculline - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Cannabinoid</topic><topic>CB1 receptor</topic><topic>Dopamine</topic><topic>Dopamine - metabolism</topic><topic>Dopamine - physiology</topic><topic>Electric Stimulation</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>GABA</topic><topic>GABA Antagonists - pharmacology</topic><topic>GABA-A Receptor Antagonists</topic><topic>gamma-Aminobutyric Acid - physiology</topic><topic>Male</topic><topic>Morpholines - pharmacology</topic><topic>Naphthalenes - pharmacology</topic><topic>Nerve Endings - drug effects</topic><topic>Nucleus accumbens</topic><topic>Nucleus Accumbens - drug effects</topic><topic>Nucleus Accumbens - metabolism</topic><topic>Piperidines - pharmacology</topic><topic>Pyrazoles - pharmacology</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Receptor, Cannabinoid, CB1 - agonists</topic><topic>Release</topic><topic>Reward</topic><topic>Vertebrates: nervous system and sense organs</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sperlágh, Beáta</creatorcontrib><creatorcontrib>Windisch, Katalin</creatorcontrib><creatorcontrib>Andó, Rómeó D.</creatorcontrib><creatorcontrib>Sylvester Vizi, E.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>MEDLINE - Academic</collection><jtitle>Neurochemistry international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sperlágh, Beáta</au><au>Windisch, Katalin</au><au>Andó, Rómeó D.</au><au>Sylvester Vizi, E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Neurochemical evidence that stimulation of CB1 cannabinoid receptors on GABAergic nerve terminals activates the dopaminergic reward system by increasing dopamine release in the rat nucleus accumbens</atitle><jtitle>Neurochemistry international</jtitle><addtitle>Neurochem Int</addtitle><date>2009-06-01</date><risdate>2009</risdate><volume>54</volume><issue>7</issue><spage>452</spage><epage>457</epage><pages>452-457</pages><issn>0197-0186</issn><eissn>1872-9754</eissn><coden>NEUIDS</coden><abstract>We examined the effect of cannabinoid receptor activation on basal and electrical field simulation-evoked (25
V, 2
Hz, 240 shocks) [
3H]dopamine efflux in the isolated rat nucleus accumbens in a preparation, in which any effect on the dendrites or somata of ventral tegmental projection neurons was excluded. The cannabinoid agonist (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone mesylate (WIN55,212-2, 100
nM) significantly enhanced stimulation-evoked [
3H]dopamine release in the presence of the selective dopamine transporter inhibitor 1-[2-[bis-(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine dihydrochloride (GBR12909, 100
nM). GBR12909 (100
nM–1
μM), when added alone, increased the evoked [
3H]dopamine efflux in a concentration-dependent manner. The stimulatory effect of WIN55,212-2 on the evoked tritium efflux was inhibited by the selective CB1 cannabinoid receptor antagonist N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (AM251, 100
nM) and by the GABA
A receptor antagonist bicuculline (10
μM). Repeated application of N-methyl-
d aspartate (1
mM) under Mg
2+-free conditions, which directly acts on dopaminergic terminals, reversibly increased the tritium efflux, but WIN55,212-2 did not affect N-methyl-
d aspartate-evoked [
3H]dopamine efflux, indicating that WIN55,212-2 has no direct action on dopaminergic nerve terminals. AM251 (100
nM) alone also did not have an effect on electrical stimulation-evoked [
3H]dopamine efflux. Likewise, the selective CB2 receptor antagonist 6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl)methanone (AM630, 0.3
μM) and the anandamide transport inhibitor (5Z,8Z,11Z,14Z)-N-(4-hydroxy-2-methylphenyl)-5,8,11,14-eicosatetraenamide (VDM11, 10
μM) had no significant effect on electrically evoked [
3H]dopamine release.
This is the first neurochemical evidence that the activation of CB1 cannabinoid receptors leads to the augmentation of [
3H]dopamine efflux via a local GABA
A receptor-mediated disinhibitory mechanism in the rat nucleus accumbens.</abstract><cop>Kidlington</cop><pub>Elsevier Ltd</pub><pmid>19428788</pmid><doi>10.1016/j.neuint.2009.01.017</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0197-0186 |
ispartof | Neurochemistry international, 2009-06, Vol.54 (7), p.452-457 |
issn | 0197-0186 1872-9754 |
language | eng |
recordid | cdi_proquest_miscellaneous_67228845 |
source | MEDLINE; Access via ScienceDirect (Elsevier) |
subjects | Anandamide Animals Benzoxazines - pharmacology Bicuculline - pharmacology Biological and medical sciences Cannabinoid CB1 receptor Dopamine Dopamine - metabolism Dopamine - physiology Electric Stimulation Fundamental and applied biological sciences. Psychology GABA GABA Antagonists - pharmacology GABA-A Receptor Antagonists gamma-Aminobutyric Acid - physiology Male Morpholines - pharmacology Naphthalenes - pharmacology Nerve Endings - drug effects Nucleus accumbens Nucleus Accumbens - drug effects Nucleus Accumbens - metabolism Piperidines - pharmacology Pyrazoles - pharmacology Rats Rats, Wistar Receptor, Cannabinoid, CB1 - agonists Release Reward Vertebrates: nervous system and sense organs |
title | Neurochemical evidence that stimulation of CB1 cannabinoid receptors on GABAergic nerve terminals activates the dopaminergic reward system by increasing dopamine release in the rat nucleus accumbens |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T04%3A04%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Neurochemical%20evidence%20that%20stimulation%20of%20CB1%20cannabinoid%20receptors%20on%20GABAergic%20nerve%20terminals%20activates%20the%20dopaminergic%20reward%20system%20by%20increasing%20dopamine%20release%20in%20the%20rat%20nucleus%20accumbens&rft.jtitle=Neurochemistry%20international&rft.au=Sperl%C3%A1gh,%20Be%C3%A1ta&rft.date=2009-06-01&rft.volume=54&rft.issue=7&rft.spage=452&rft.epage=457&rft.pages=452-457&rft.issn=0197-0186&rft.eissn=1872-9754&rft.coden=NEUIDS&rft_id=info:doi/10.1016/j.neuint.2009.01.017&rft_dat=%3Cproquest_cross%3E20068399%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20068399&rft_id=info:pmid/19428788&rft_els_id=S0197018609000357&rfr_iscdi=true |